Komori
Fuso Pharmaceutical Industries (4538) · RiskRestated

Accounts receivable collection risk arising from deterioration in business partners’ financial condition

First written in FY2021. 5 of 6 entries say "Restated". Latest entry: FY2024.

6entries
4years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2021 – FY20242021: 120212022: 120222023: 220232024: 22024
Same theme, other companies
Managing Counterparty Credit RiskA theme 903 companies write about · 923 as a headwind · 18 as a tailwind

The whole theme swung hardest in 2026: 19 of 65 companies on the "Worse" side.

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 194 companies compared. The sentences above are computed from all 194.Comparing 200 of the theme's 942 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2024RestatedAnnual report

    「In accordance with its sales administration regulations, accounting regulations and other policies, the Sales Division and General Affairs Division regularly monitor the status of major customers, manage due dates and outstanding balances for each counterparty, seek to identify early any collection concerns arising from deterioration in financial condition or other factors, and mitigate collection-related risks by receiving advance payments.」

    The Company continues to address collection risks through monitoring of major customers, management of due dates and outstanding balances, and receipt of advance payments.
  2. FY2024-Q3RestatedAnnual report

    「During the first three quarters of the current fiscal year, there were no new occurrences of the major risks that management recognises could materially affect the filing company's financial position, operating results or cash flows among the matters relating to business conditions, financial conditions and other matters described in the quarterly report, and no material changes to the "Business and Other Risks" described in the annual securities report for the previous fiscal year.」

    The Company stated that there had been no material changes regarding the risk of collecting receivables due to deterioration in customers' financial condition.
  3. FY2024-Q1RestatedAnnual report

    「There were no new major risks during the three months ended 30 June, and no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」

    The Company stated that there had been no material changes regarding the risk of collecting receivables due to deterioration in customers' financial condition.
  4. FY2023-Q3RestatedAnnual report

    「During the first three quarters of the current fiscal year, there were no new occurrences of the major risks that management recognises could materially affect the filing company's financial position, operating results or cash flows among the matters relating to business conditions, financial conditions and other matters described in the quarterly report, and no material changes to the "Business and Other Risks" described in the annual securities report for the previous fiscal year.」

    The Company stated that there had been no material changes regarding the risk of collecting receivables due to deterioration in customers' financial condition.
  5. FY2022RestatedAnnual report

    「In accordance with its sales administration regulations, accounting regulations and other policies, the Sales Division and General Affairs Division regularly monitor the status of major customers, manage due dates and outstanding balances for each counterparty, seek to identify early any collection concerns arising from deterioration in financial condition or other factors, and mitigate collection-related risks by receiving advance payments. However, if collection of receivables is delayed due to an unexpected deterioration in a customer's financial condition or other factors, this could have a material impact on the Company's operating results and financial condition.」

    The Company continues to address collection risks through customer monitoring, management of due dates and outstanding balances, and receipt of advance payments, and continues to disclose the potential impact on operating results if collection is delayed.
  6. FY2021First statedAnnual report

    「In accordance with its sales administration regulations, accounting regulations and other policies, the Sales and General Affairs Divisions regularly monitor the status of major customers, manage due dates and outstanding balances for each counterparty, seek to identify early any collection concerns arising from deterioration in financial condition or other factors, and mitigate these concerns by receiving advance payments. However, if collection of receivables is delayed due to an unexpected deterioration in a customer's financial condition or other factors, this could have a material impact on the Company's operating results and financial condition.」

    The Company newly identified delays in collecting trade receivables due to deterioration in customers' financial condition and other factors as a major risk, and described measures including customer monitoring, management of due dates and outstanding balances, and receipt of advance payments.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Fuso Pharmaceutical Industries yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.